SAN DIEGO, Feb. 04, 2016 -- Medical Marijuana, Inc.’s (OTC Pink:MJNA) is proud to inform shareholders and the public that Reuters wire news agency featured the Company in the article California-based Medical Marijuana Eyes Mexico as Next Big Market. In an historic move, the government of Mexico issued two of the country’s first permits to import a cannabidiol product, RSHO-X, from the U.S. headquartered industrial hemp company.
“With Mexico’s government’s decision to approve import permits, we are extremely proud of our capability to provide our cannabidiol (CBD) hemp oil, RSHO-X, to the more than 120 million residents of Mexico,” states Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “Our overall mission is ‘access for all’ and this is a major milestone achievement.”
According to the Reuters report, imports to Mexico are “restricted to products free of tetrahydrocannabinol (THC), the ingredient in marijuana that gets you 'high'.” RSHO-X contains cannabidiol, the non-psychoactive component of the hemp plant.
Reuters continues, “With a population of 120 million people, Mexico could eventually provide a sizeable market for marijuana investors.” The report estimates the market in Mexico for cannabidiol (CBD) hemp oil to be $1-2 billion over ten years.
Additional reports include Fortune and Business Insider. Details of the COFEPRIS announcement can be found here: http://www.cofepris.gob.mx/Documents/NotasPrincipales/01022016.pdf
Additional information is listed on the HempMeds® Mexico website. For more information on RSHO-X, visit http://www.hempmeds.mx
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company, created to provide access to cannabinoid-based products including cannabidiol (CBD) hemp oil products as they become legal in the country of Mexico for the first time. Our Company is a sales, marketing and distribution company. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to our CBD hemp oil products. HempMeds® Mexico is the first company to legally ship RSHO-X CBD hemp oil into Mexico. For more information, please review the company’s website at: http://hempmeds.mx/.
About HempMeds®
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds® is the communication hub for the Medical Marijuana Inc. portfolio of companies.
About Medical Marijuana Inc.
The mission of Medical Marijuana, Inc. (OTC Pink:MJNA) is to be the premier hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company's website at: www.MedicalMarijuanaInc.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact:
Public Relations contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
[email protected]
www.cmwmedia.com
Corporate contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc


Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 



